title: Efficacy of percutaneous cementoplasty for bone metastasis from hepatocellular carcinoma.
abstract: OBJECTIVE
  To assess the efficacy of percutaneous cementoplasty for painful bone metastasis from hepatocellular carcinoma (HCC).
  
  
  METHODS
  Cementoplasty was performed for 22 metastatic bone tumors in 13 patients. All patients had intractable pain and were diagnosed as metastatic bone tumor from HCC. The ostyneedle was inserted in the center of the site of bone metastasis under CT guidance. VAS score, Tokuhashi score and Frankel score were used for assessment of the efficacy of cementoplasty. We also assessed the response to treatment, adverse events and prognosis.
  
  
  RESULTS
  Only the VAS score, but not Tokuhashi and Frankel scores, improved after cementoplasty. Cementoplasty for painful bone metastasis provided relief of severe pain but did not improve prognosis, neurological function or survival. Eleven of 13 (85%) patients showed CR or PR and the mean pain-free period was 5 months, including a 10-month pain-free period in one case. No major complications were encountered.
  
  
  CONCLUSIONS
  Percutaneous cementoplasty can provide pain relief and improvement of quality of life, though without survival benefits, for HCC patients with painful bone metastasis.
authors.affiliation: Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, Minami-ku, Hiroshima, Japan.
authors.forename: Hideaki
authors.initials: H
authors.lastname: Kodama
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Aikata
authors.forename: Kiminori
authors.initials: K
authors.lastname: Uka
authors.forename: Shintaro
authors.initials: S
authors.lastname: Takaki
authors.forename: Nami
authors.initials: N
authors.lastname: Mori
authors.forename: Koji
authors.initials: K
authors.lastname: Waki
authors.forename: Soo Cheol
authors.initials: SC
authors.lastname: Jeong
authors.forename: Yoshiiku
authors.initials: Y
authors.lastname: Kawakami
authors.forename: Hiroo
authors.initials: H
authors.lastname: Shirakawa
authors.forename: Shoichi
authors.initials: S
authors.lastname: Takahashi
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Toyota
authors.forename: Katsuhide
authors.initials: K
authors.lastname: Ito
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Chayama
mesh_terms: D000368:Aged; D001843:Bone Cements / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000150:complications / Q000556:secondary / Q000628:therapy*; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000556:secondary / Q000628:therapy*; D006801:Humans; D015552:Injections, Intralesional; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000209:etiology; D059408:Pain Management; D011788:Quality of Life; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D001843:Bone Cements